Caspofungin-non-susceptible Candida isolates in cancer patients

J Antimicrob Chemother. 2010 Feb;65(2):293-5. doi: 10.1093/jac/dkp444. Epub 2009 Dec 16.

Abstract

Objectives: To identify the frequency of caspofungin-non-susceptible Candida isolates in cancer patients with candidiasis.

Methods: We reviewed the in vitro susceptibilities (M27-A3 CLSI method) of 650 Candida spp. associated with invasive candidiasis episodes in 582 hospitalized cancer patients (2005-08).

Results and conclusions: We identified seven caspofungin-non-susceptible Candida strains (three Candida tropicalis, two Candida glabrata and two Candida albicans) from 650 Candida isolates (1%). C. tropicalis (three out of seven) was the most common non-susceptible species isolated. All patients responded to a change of antifungal therapy. Further surveillance should focus on the potential broader emergence of echinocandin resistance, as the clinical use of this antifungal class continues to expand in cancer patients.

MeSH terms

  • Adolescent
  • Aged
  • Aged, 80 and over
  • Antifungal Agents / pharmacology*
  • Candida albicans / drug effects*
  • Candida albicans / isolation & purification
  • Candida glabrata / drug effects*
  • Candida glabrata / isolation & purification
  • Candida tropicalis / drug effects*
  • Candida tropicalis / isolation & purification
  • Candidiasis / microbiology*
  • Caspofungin
  • Drug Resistance, Fungal*
  • Echinocandins / pharmacology*
  • Female
  • Humans
  • Lipopeptides
  • Male
  • Middle Aged
  • Neoplasms / complications*
  • Young Adult

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Caspofungin